Sorafenib Prophylaxis Is Effective in Preventing Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients

被引：0
|
作者：
Saab, Sammy [1 ]
McTigue, Mike [1 ]
Finn, Richard [1 ]
Busuttil, Ronald W. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
LIVER TRANSPLANTATION | 2010年 / 16卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [21] Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence
    Jung, Dong-Hwan
    Tak, Eunyoung
    Hwang, Shin
    Song, Gi-Won
    Ahn, Chul-Soo
    Kim, Ki-Hun
    Moon, Deok-Bog
    Ha, Tae-Yong
    Park, Gil-Chun
    Ryoo, Baek-Yeol
    Lee, Kyung Jin
    Kim, Nayoung
    Kwon, Jae-Hyeon
    Jwa, Eun-Kyoung
    Lee, Sung-Gyu
    LIVER TRANSPLANTATION, 2018, 24 (07) : 932 - 945
  • [22] EVEROLIMUS AND SORAFENIB FOR RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    De Simone, Paolo
    Pezzati, Daniele
    Lai, Quirino
    Ghinolfi, Davide
    Coletti, Laura
    Precisi, Arianna
    Leonardi, Giulia
    Carrai, Paola
    Filipponi, Franco
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293
  • [23] Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
    Kang, Seong Hee
    Cho, Hyeki
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yi, Nam-Joon
    Lee, Kwang-Woong
    Suh, Kyung-Suk
    Yoon, Jung-Hwan
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (45)
  • [24] Sorafenib As Adjuvant Therapy For High-Risk Hepatocellular Carcinoma in Liver Transplant Recipients: Feasibility and Efficacy
    Saab, Sammy
    McTigue, Michael
    Finn, Richard S.
    Busuttil, Ronald W.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2010, 8 (04) : 307 - 313
  • [25] Post-Transplant Recurrence Following Yttrium-90 Treatment in Liver Transplant Recipients with Hepatocellular Carcinoma
    Rizzo, O.
    Kitajima, T.
    Kavousi, M.
    Yeddula, S.
    Rizzari, M.
    Collins, K.
    Yoshida, A.
    Abouljoud, M. S.
    Nagai, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 1057 - 1057
  • [26] Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
    Salerno, D.
    Lange, N.
    Simoneau, E.
    Sammons, C.
    Bley, D.
    Brown, R. S., Jr.
    Emond, J.
    Halazun, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1071 - 1072
  • [27] Strategies of Immunosuppression for Liver Transplant Recipients With Hepatocellular Carcinoma
    Castroagudin, J. F.
    Molina-Perez, E.
    Ferreiro-Iglesias, R.
    Varo-Perez, E.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (03) : 711 - 713
  • [28] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
    Fayek, Sameh Adel
    Mantipisitkul, Wana
    Rasetto, Flavia
    Munivenkatappa, Raghava
    Barth, Rolf N.
    Philosophe, Benjamin
    HPB, 2010, 12 (10) : 657 - 663
  • [29] Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplant
    Bansal, Sourav
    Dommaraju, Sunil
    Thaker, Sarang
    Karimi, Saman
    Guzman, Grace
    Di Cocco, Pierpaolo
    Benedetti, Enrico
    Koppe, Sean
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S1991 - S1991
  • [30] Management of liver transplant patients with recurrence of hepatocellular carcinoma
    Safak, Adem
    Karakaya, Emre
    Yildirim, Sedat
    Okyay, Ozan
    Boyvat, Fatih
    Tseveldorj, Nomingerel
    Boyacioglu, Sedat
    Haberal, Mehmet A.
    TRANSPLANTATION, 2024, 108 (09) : 648 - 648
12345